Phase 2 Head and Neck Cancer Trial, Recruiting NCT07248956 Sponsor: Eye & ENT Hospital of Fudan University Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT07248956
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to sign a written consent form agreeing to take part
  • People aged 18 to 75 years old
  • People who have not yet received any treatment for their cancer
  • People who have been diagnosed with a certain stage of throat cancer (specifically hypopharyngeal carcinoma, stage III or IVA) that can be surgically removed, and whose tumour shrank by at least 50% after initial pre-treatment (confirm with trial site)
  • People whose general health and ability to carry out daily activities falls within an acceptable range as assessed by their doctor (confirm with trial site)

Who may not be able to join:

  • People who are pregnant or currently breastfeeding
  • People who have had a serious allergic reaction to either of the study medicines (sintilimab or nab-paclitaxel) or any of their ingredients
  • People who have heart or blood vessel problems, or other health conditions, that are not well managed or controlled
  • People who have an active autoimmune disease, or a history of one, that has required ongoing medical treatment
  • People who have, or have previously had, a second unrelated cancer
  • People whose doctors consider them unsuitable for the trial for any other medical reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ming Zhang, PhD, Eye & ENT Hospital, Fudan University

Phone: 021-64377134

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Eye & ENT Hospital of Fudan University
Registry
ClinicalTrials.gov
Start date
22 December 2025
Est. completion
30 November 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Event-free survival (EFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov